Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Cureus ; 15(8): e44283, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-37779745

RESUMEN

Tumors arising from burn scars are not rare but sometimes cause the rare co-existence of different tumors. However, detailed information on this topic remains largely unknown. We present a case of the co-occurrence of malignant melanoma and squamous cell carcinoma in a patient with a history of burn scars. A 73-year-old man presented with an erythematous plaque on his left lower leg that gradually turned into a tumor with ulceration. He also presented with scaly tumors at other sites within the same burn scar lesion. He had a history of burns on the left leg at the age of 20 years. After surgical resection of the tumors, histological analysis revealed that the posterior aspect of the largest tumor was malignant melanoma, and the remaining two tumors were squamous cell carcinomas, indicating the co-existence of different types of malignant skin cancers. Based on a literature review of previously published case reports, this is the first report to highlight the importance of complete skin grafts in reducing this risk.

5.
Sci Rep ; 8(1): 5522, 2018 04 03.
Artículo en Inglés | MEDLINE | ID: mdl-29615641

RESUMEN

The anti-inflammatory effect of omega 3 polyunsaturated fatty acids has been confirmed in various inflammatory disease models. Maresin-1 (MaR1) is a lipid mediator derived from the omega-3 fatty acid docosahexaenoic acid (DHA) that has displayed strong anti-inflammatory effects in various inflammatory disease models. However, the effect of topical MaR1 on cutaneous inflammation remains unclear. Therefore, we initially examined the anti-inflammatory effects of topical Maresin-1 using an imiquimod (IMQ)-induced psoriasis-like mouse model of inflammation. Topical MaR1 reduced the ear swelling response as seen in histological findings. RT-PCR and flow cytometry analyses revealed MaR1 had no inhibitory effect on IL-23, but MaR1 suppressed IL-17A production by γδTCRmid+ and CD4+ cells in the skin. These inhibitory effects were also observed in a subcutaneous IL-23-injected psoriasis model. MaR1 downmodulated IL-23 receptor (IL-23R) expression by suppressing retinoic acid-related orphan receptor γt (RORγt) expression and internalization in a clathrin-dependent manner in γδTCRmid+ and CD4+ cells. These results lead to assumptions that topical MaR1 may be a new therapeutic agent for psoriasis and other IL-17-mediated cutaneous inflammatory diseases.


Asunto(s)
Ácidos Docosahexaenoicos/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Imiquimod/farmacología , Receptores de Interleucina/metabolismo , Piel/efectos de los fármacos , Animales , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/metabolismo , Ácidos Docosahexaenoicos/uso terapéutico , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Interleucina-17/biosíntesis , Linfocitos Intraepiteliales/efectos de los fármacos , Linfocitos Intraepiteliales/metabolismo , Ratones , Piel/inmunología , Piel/metabolismo
9.
Intern Med ; 56(18): 2471-2474, 2017 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-28824076

RESUMEN

A 78-year-old man presented with cutaneous blisters of the limbs and abdominal distension. He had been treated for various diseases, including liver cirrhosis. He had begun receiving sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for diabetes mellitus three years before the hospitalization. A skin biopsy demonstrated bullous pemphigoid. Ultrasonography (US) revealed multiple liver tumors, although he had been receiving regular US studies. We stopped sitagliptin and started insulin and corticosteroids. However, his renal dysfunction progressed, and he died 14 days after the hospitalization. We should therefore be careful of various complications, including bullous pemphigoid and progression of tumors, when using DPP-4 inhibitors.


Asunto(s)
Carcinoma Hepatocelular/patología , Inhibidores de la Dipeptidil-Peptidasa IV/efectos adversos , Cirrosis Hepática/patología , Neoplasias Hepáticas/patología , Penfigoide Ampolloso/inducido químicamente , Fosfato de Sitagliptina/efectos adversos , Anciano , Diabetes Mellitus/tratamiento farmacológico , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Humanos , Hipoglucemiantes/efectos adversos , Masculino , Fosfato de Sitagliptina/uso terapéutico
19.
Springerplus ; 5(1): 1112, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27478729

RESUMEN

BACKGROUND: An anaphylactoid purpura affects small capillaries in the skin and other organs. Although two cases of anaphylactoid purpura exacerbated by cellulitis have been reported in Japanese literatures, its prognosis remains still unclear. Because cellulitis exacerbates various cutaneous inflammations, it has been speculated that cellulitis might also exacerbate cutaneous inflammation, such as vasculitis. FINDINGS: In this article, we report that 78-year-old woman exhibited anaphylactoid purpura, following cellulitis. We also reviewed the literature concerning about this subject. CONCLUSIONS: This type of anaphylactoid purpura is thought to have a favorable prognosis dependent on the treatment for cellulitis.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...